These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 17899489)

  • 1. Epigenetic alterations and cancer: new targets for therapy.
    Allen A
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
    Grønbaek K; Treppendahl M; Asmar F; Guldberg P
    Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approaches on epigenetics.
    Papait R; Monti E; Bonapace IM
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
    Li LC; Carroll PR; Dahiya R
    J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenome: a new target in cancer therapy.
    Giacinti L; Vici P; Lopez M
    Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
    Murgo AJ
    Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic gene regulation in cancer.
    Ballestar E; Esteller M
    Adv Genet; 2008; 61():247-67. PubMed ID: 18282509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic opportunities and challenges in cancer.
    Best JD; Carey N
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone modification enzymes: novel targets for cancer drugs.
    Kristeleit R; Stimson L; Workman P; Aherne W
    Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R; Ocker M
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic drugs take on cancer.
    Kaiser J
    Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinical application of targeting cancer through histone acetylation and hypomethylation.
    Gilbert J; Gore SD; Herman JG; Carducci MA
    Clin Cancer Res; 2004 Jul; 10(14):4589-96. PubMed ID: 15269129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic changes in cancer.
    Grønbaek K; Hother C; Jones PA
    APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
    Bhalla KN
    J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.